Compare Stocks → The asset beating inflation by 4x (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CVACNASDAQ:MLYSNYSE:NUVBNASDAQ:VERV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$3.13+13.0%$2.99$2.21▼$12.36$700.74M2.51687,712 shs1.78 million shsMLYSMineralys Therapeutics$12.95-1.1%$13.03$5.85▼$17.70$642.72M2.05126,021 shs71,821 shsNUVBNuvation Bio$3.22-1.5%$2.72$0.95▼$4.16$702.11M1.421.24 million shs894,598 shsVERVVerve Therapeutics$6.41+4.2%$10.94$5.84▼$21.42$537.95M1.941.12 million shs1.39 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac0.00%+34.33%+5.74%-10.83%-55.09%MLYSMineralys Therapeutics0.00%+9.10%+2.70%+6.50%-8.80%NUVBNuvation Bio0.00%+20.15%-7.47%+103.80%+101.25%VERVVerve Therapeutics0.00%+4.06%-26.15%-41.78%-60.31%The asset beating inflation by 4x (Ad)"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the detailsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac3.8802 of 5 stars3.04.00.04.92.50.00.6MLYSMineralys Therapeutics1.9371 of 5 stars3.52.00.00.00.05.00.0NUVBNuvation Bio3.2484 of 5 stars4.53.00.00.01.73.30.0VERVVerve Therapeutics2.4036 of 5 stars3.40.00.00.02.04.21.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac2.00Hold$8.33166.24% UpsideMLYSMineralys Therapeutics3.00Buy$33.50158.69% UpsideNUVBNuvation Bio3.00Buy$6.60104.97% UpsideVERVVerve Therapeutics2.75Moderate Buy$33.00414.82% UpsideCurrent Analyst RatingsLatest VERV, CVAC, NUVB, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024CVACCureVacLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/25/2024CVACCureVacSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $4.004/17/2024NUVBNuvation BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.004/8/2024VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/5/2024CVACCureVacGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral4/3/2024VERVVerve TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $40.004/2/2024MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/28/2024NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/27/2024NUVBNuvation BioJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$1.40 ➝ $10.003/26/2024MLYSMineralys TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/26/2024NUVBNuvation BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$58.18M12.04N/AN/A$2.50 per share1.25MLYSMineralys TherapeuticsN/AN/AN/AN/A$5.87 per shareN/ANUVBNuvation BioN/AN/AN/AN/A$2.76 per shareN/AVERVVerve Therapeutics$11.76M45.74N/AN/A$7.31 per share0.88Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac-$281.58MN/A0.00N/AN/A-483.85%-41.87%-29.65%6/4/2024 (Estimated)MLYSMineralys Therapeutics-$71.90M-$2.00N/AN/AN/AN/A-26.48%-25.52%5/9/2024 (Confirmed)NUVBNuvation Bio-$75.80M-$0.34N/AN/AN/AN/A-12.21%-11.89%N/AVERVVerve Therapeutics-$200.07M-$3.12N/AN/AN/A-1,701.70%-39.33%-30.92%5/20/2024 (Estimated)Latest VERV, CVAC, NUVB, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AMLYSMineralys Therapeutics-$0.68N/A+$0.68N/AN/AN/A 3/21/2024Q4 2023MLYSMineralys Therapeutics-$0.85-$0.61+$0.24-$0.61N/AN/A 2/29/2024Q4 2023NUVBNuvation Bio-$0.10-$0.06+$0.04-$0.06N/AN/A2/27/2024Q4 2023VERVVerve Therapeutics-$0.83-$0.69+$0.14-$0.69$3.95 million$5.14 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.072.572.43MLYSMineralys TherapeuticsN/A23.7623.76NUVBNuvation BioN/A44.1144.11VERVVerve TherapeuticsN/A17.2417.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%MLYSMineralys Therapeutics84.46%NUVBNuvation Bio61.67%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipCVACCureVac2.15%MLYSMineralys Therapeutics33.24%NUVBNuvation Bio36.09%VERVVerve Therapeutics21.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac1,049223.88 million219.07 millionOptionableMLYSMineralys Therapeutics2849.63 million33.13 millionOptionableNUVBNuvation Bio51218.05 million139.35 millionOptionableVERVVerve Therapeutics25583.92 million65.96 millionOptionableVERV, CVAC, NUVB, and MLYS HeadlinesSourceHeadlineVerve Therapeutics (NASDAQ:VERV) Trading 7.8% Higher americanbankingnews.com - May 5 at 4:34 AMVerve Therapeutics (NASDAQ:VERV) Trading Up 7.8%marketbeat.com - May 3 at 9:33 PMVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 3 at 4:01 PMVerve Therapeutics (NASDAQ:VERV) Reaches New 12-Month Low at $5.93americanbankingnews.com - May 3 at 5:20 AMVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $5.93marketbeat.com - May 1 at 12:28 PMVerve Therapeutics (NASDAQ:VERV) Reaches New 1-Year Low at $6.05americanbankingnews.com - April 27 at 5:32 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 25 at 5:15 PMVerve Therapeutics (NASDAQ:VERV) Hits New 52-Week Low at $6.05marketbeat.com - April 25 at 3:44 PMSumitomo Mitsui Trust Holdings Inc. Grows Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)marketbeat.com - April 21 at 5:16 AMFederated Hermes Inc. Purchases 1,448,003 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)marketbeat.com - April 20 at 7:16 AMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 19 at 4:00 AMGV’s Newest Life Sciences General Partner Pursues Precision Treatmentswsj.com - April 18 at 9:55 AMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 18 at 8:00 AMVerve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77msn.com - April 18 at 12:03 AMVerve Therapeutics (NASDAQ:VERV) Stock Price Down 2.9%marketbeat.com - April 17 at 12:20 PMVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $7.26marketbeat.com - April 15 at 2:48 PMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 13 at 8:00 PMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 13 at 6:00 AMIMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 12 at 4:30 AMTop 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarterbenzinga.com - April 11 at 8:46 AMCRISPR-based innovations drove $21 billion in pharmaceutical licensing deals over five years: GlobalDatahealth.economictimes.indiatimes.com - April 10 at 9:48 AMBuy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recoverymarkets.businessinsider.com - April 9 at 8:55 AMA Bold Gene-Editing Solution Began Testing—Then Hit the Strangest Twistmsn.com - April 9 at 8:55 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 9 at 3:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesWhat is the Nasdaq? Complete Overview with HistoryApril 16, 2024 8:00 AMView What is the Nasdaq? Complete Overview with HistoryAll Headlines Company DescriptionsCureVacNASDAQ:CVACCureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Mineralys TherapeuticsNASDAQ:MLYSMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Nuvation BioNYSE:NUVBNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Verve TherapeuticsNASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.